Haemonetics Corporation (HAE) Q4 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello, and welcome to the Q4 2026 Hemonetics Corporations Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to Olga Goyet, Vice President of Investor Relations and Treasury. Please go ahead. Good morning, and thank you for joining us for Humanetics' fourth quarter fiscal year 2026 conference call and webcast. I'm joined today by Chris Simon, our CEO, and James Dureka, our CFO. This morning, we released our fourth quarter and full fiscal 2026 results and issued fiscal year 2027 guidance. The materials, including our earnings release and supplemental earnings presentation, are available on our Investor Relations website and also in this morning's press release. Before we begin, I'd like to remind everyone that we will use both reported and organic revenue growth rates that exclude the impact of effects, the divestiture of the whole blood product line, and the exit of certain liquid solutions products. Organic Growth Act CSL also excludes the impact of the previously disclosed transition of CSL's U.S. disposable business. Our fiscal year 2027 organic revenue guidance is also adjusted for the impact of the 53rd week. We'll refer to other non-GAAP financial measures to help investors understand humanetics ongoing business performance. Please note that these measures exclude certain charges and income items. A full list of excluded items Reconcili...